<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Vet. Med. Sci</journal-id><journal-id journal-id-type="publisher-id">JVMS</journal-id><journal-title-group><journal-title>The Journal of Veterinary Medical Science</journal-title></journal-title-group><issn pub-type="ppub">0916-7250</issn><issn pub-type="epub">1347-7439</issn><publisher><publisher-name>The Japanese Society of Veterinary Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4829508</article-id><article-id pub-id-type="pmid">26596634</article-id><article-id pub-id-type="publisher-id">15-0255</article-id><article-id pub-id-type="doi">10.1292/jvms.15-0255</article-id><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject><subj-group><subject>Full Paper</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="39917" pm="."><plain>Analyses of a satiety factor NUCB2/nesfatin-1; gene expressions andmodulation by different dietary components in dogs </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>NOZAWA</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>KIMURA</surname><given-names>Tomoko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>KURISHIMA</surname><given-names>Miyuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>MIMURA</surname><given-names>Kana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>SAEKI</surname><given-names>Kaori</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>MIKI</surname><given-names>Yohei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>ODA</surname><given-names>Hitomi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>MORI</surname><given-names>Akihiro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>MOMOTA</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>AZAKAMI</surname><given-names>Daigo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>ISHIOKA</surname><given-names>Katsumi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><aff id="aff1"><label>1)</label>Department of Veterinary Nursing, School of Veterinary
Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science
University, 1–7–1 Kyonan-cho, Musashino-shi, Tokyo 180–8602, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Ishioka, K., Department of Veterinary
Nursing, School of Veterinary Nursing and Technology, Faculty of Veterinary Science,
Nippon Veterinary and Life Science University, 1–7–1 Kyonan-cho, Musashino-shi, Tokyo
180–8602, Japan. e-mail: <email xlink:href="katsumi@nvlu.ac.jp">katsumi@nvlu.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2016</year></pub-date><volume>78</volume><issue>3</issue><fpage>411</fpage><lpage>417</lpage><history><date date-type="received"><day>28</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>©2016 The Japanese Society of Veterinary Science</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="39918" pm="."><plain>Nesfatin-1 is an anorexic peptide derived from a precursor, nucleobindin-2 (NUCB2), which is distributed in various organs, coexists with ghrelin in the gastric X/A-like cells and closely relates to an appetite control in rodents and humans. </plain></SENT>
<SENT sid="39919" pm="."><plain>Nesfatin-1 may be a significant factor addressing the satiety also in veterinary medicine, however, there are few reports about nesfatin-1 in dogs. </plain></SENT>
<SENT sid="39920" pm="."><plain>In the present study, we detected canine NUCB2/nesfatin-1 mRNA in various tissues, especially abundant in pancreas, gastrointestinal tracts, testis and cerebellum. </plain></SENT>
<SENT sid="39921" pm="."><plain>We examined circulating nesfatin-1 concentrations and NUCB2/nesfatin-1 mRNA expressions in upper gastrointestinal tracts (gastric corpus, pyloric antrum and duodenum) in dogs fed on different types of diets. </plain></SENT>
<SENT sid="39922" pm="."><plain>Plasma nesfatin-1 concentrations in the dogs were approximately 4 ng/ml and they did not change after feeding through the study, however, NUCB2/nesfatin-1 mRNA expressions in pyloric antrum were 1.84-fold higher in the dogs fed on a High fiber/High protein diet (P&lt;0.001), 1.48-fold higher in the dogs fed on a High fat/Low protein diet (P&lt;0.05) and 1.02-fold higher in the dogs fed on a Low fat/High carbohydrate diet (not significant) comparing to those on a control diet. </plain></SENT>
<SENT sid="39923" pm="."><plain>It was concluded that High fiber/High protein and High fat/Low protein diets increased NUCB2/nesfatin-1 production in canine gastrointestinal tracts. </plain></SENT>
<SENT sid="39924" pm="."><plain>These results may set the stage for further investigations of canine NUCB2/nesfatin-1, which may relate to satiety effects in dogs. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>anorexic peptide</kwd><kwd>canine</kwd><kwd>nesfatin-1</kwd><kwd>nucleobindin-2</kwd><kwd>obesity</kwd></kwd-group></SecTag></article-meta></front><body><p><text><SENT sid="39925" pm="."><plain>Obesity is defined as excessive body fat accumulation, and the prevalence of obesity in dogs has increased in recent years [3]. </plain></SENT>
<SENT sid="39926" pm="."><plain>Obese dogs have higher risks in hyperlipidemia, pancreatitis, arthritic disorders and shortened life-span, so it is considered to be a condition which must be treated [6, 14]. </plain></SENT>
<SENT sid="39927" pm="."><plain>Obesity is basically caused by overfeeding and/or less exercise, so the dietary restriction is a key technique for a weight control. </plain></SENT>
<SENT sid="39928" pm="."><plain>However, simply reduced energy feeding causes begging behaviors to animals, and the development of reducing diets with enough satiety effects is an important challenge. </plain></SENT>
<SENT sid="39929" pm="."><plain>However, it is difficult to assess the feeling of satiety in animals, because it is a subjective sense which can not be determined by routine techniques. </plain></SENT>
<SENT sid="39930" pm="."><plain>Recently, it has been revealed that many peptides are involved in the eating behavior in rodents, humans and dogs. </plain></SENT>
<SENT sid="39931" pm="."><plain>For example, leptin is a representative adipokine that is produced by adipocytes and suppresses appetite. </plain></SENT>
<SENT sid="39932" pm="."><plain>In contrast, ghrelin is a peptide produced in the stomach and increases appetite. </plain></SENT>
<SENT sid="39933" pm="."><plain>We have investigated the functions and clinical usefulness of these peptides in cats and dogs, and discovered that leptin is available as an obese marker in dogs and ghrelin functions as a feeding stimulant in cats and dogs [12]. </plain></SENT>
</text></p><p><text><SENT sid="39934" pm="."><plain>Nesfatin-1 is an 82-amino acid peptide derived from the precursor, NEFA/nucleobindin-2 (NUCB2), in humans and rodents [19]. </plain></SENT>
<SENT sid="39935" pm="."><plain>Centrally, PVN-NTS-Melanocortin (MC) 3/4 receptors function as the appetite control center [7, 15, 18, 34]. </plain></SENT>
<SENT sid="39936" pm="."><plain>Nesfatin-1 stimulates afferent vagal nerve cells locally and increases the pro-opiomelanocortin (POMC) mRNA expression in NTS through the afferent nerve system. </plain></SENT>
<SENT sid="39937" pm="."><plain>Alpha-melanocyte-stimulating hormone which forms by processing of POMC inhibits appetite via MC 3/4 receptors [17, 26]. </plain></SENT>
<SENT sid="39938" pm="."><plain>Nesfatin-1 has been detected in appetite-control hypothalamic nuclei and in many peripheral tissues, such as stomach, adipose tissue, pancreas, pituitary gland and testis of the rat and goldfish [8, 11, 27, 29, 35]. </plain></SENT>
<SENT sid="39939" pm="."><plain>In particular, Stengel et al. [27] have reported that NUCB2 mRNA expression in gastric mucosa was 10 times of that in brain in rats. </plain></SENT>
<SENT sid="39940" pm="."><plain>Additionally, nesfatin-1 suppresses food consumption when it was administered to rats centrally or peripherally [18, 26]. </plain></SENT>
<SENT sid="39941" pm="."><plain>It has been hypothesized that peripheral nesfatin-1 acts via the blood-brain barrier [20, 23] or the afferent vagal nerves [1, 25, 36], however, the detail pathways underlying its action are unknown at present. </plain></SENT>
</text></p><p><text><SENT sid="39942" pm="."><plain>NUCB2/nesfatin-1 is located in the gastric X/A-like cells coexisting with ghrelin [27], and the NUCB2 mRNA and nesfatin-1 protein are affected by fasting/refeeding cycles in rodent [24]. </plain></SENT>
<SENT sid="39943" pm="."><plain>Moreover, Gonkowski et al. [10] have detected nesfatin-1 -like immunoreactive cells in the mucosal layer of the canine digestive tracts, and Watanabe et al. [31] have reported that nesfatin-1 inhibited gastric contractions in the fasted state when administrated to dogs. </plain></SENT>
<SENT sid="39944" pm="."><plain>In this way, the relationship between nesfatin-1 and gastrointestinal tracts is focused also in veterinary science. </plain></SENT>
<SENT sid="39945" pm="."><plain>However, there are few reports about nesfatin-1 in dogs. </plain></SENT>
</text></p><p><text><SENT sid="39946" pm="."><plain>In the present study, we demonstrated following experiments for the purpose of better understanding of canine NUCB2/nesfatin-1, i.e. 1) we cloned cDNA of canine NUCB2/nesfatin-1 and revealed the tissue distribution, especially in the upper gastrointestinal tracts, 2) we investigated the change of plasma nesfatin-1 concentrations before and after feeding of different types of diets, and 3) we investigated the change of mRNA expressions of NUCB2/nesfatin-1 in the stomach and duodenum of the dogs fed on different types of diets chronically, which may relate to possible satiety effects. </plain></SENT>
<SENT sid="39947" pm="."><plain>Focus is on the gene expression of nesfatin-1 in the gastrointestinal system, because they are directly contacting organs to dietary components. </plain></SENT>
</text></p><SecTag type="METHODS"><sec sec-type="materials|methods" id="s1"><title><text><SENT sid="39948" pm="."><plain>MATERIALS AND METHODS </plain></SENT>
</text></title><p><text><SENT sid="39949" pm="."><plain>Sample preparation: Canine tissue samples collected and kept frozen for other research were used for RNA extraction in this study. </plain></SENT>
<SENT sid="39950" pm="."><plain>Total RNAs of the 14 canine tissues (cerebrum, cerebellum, esophagus, stomach, pancreas, small intestine, liver, heart, spleen, kidney, bladder, skeletal muscle, testis and adipose tissue) were extracted by homogenizing each sample (50–150 mg) in TRI Reagent (Sigma, St. Louis, MO, U.S.A.). </plain></SENT>
<SENT sid="39951" pm="."><plain>For more detailed analysis of NUCB2/nesfatin-1 expressions in canine upper-gastrointestinal tracts, 4 kinds of tissues (gastric fundus, gastric corpus, pyloric antrum and duodenum) were sampled using an endoscope from a healthy dog which were used in the following study. </plain></SENT>
<SENT sid="39952" pm="."><plain>Total RNA was extracted using RNeasy Plus Mini Kit (QIAGEN, Tokyo, Japan). </plain></SENT>
</text></p><p><text><SENT sid="39953" pm="."><plain>Cloning and sequencing of canine NUCB2/nesfatin-1: Genome sequence information of canine NUCB2/nesfatin-1 was obtained from the GenBank (accession, XM534078). </plain></SENT>
<SENT sid="39954" pm="."><plain>The designed primer sequences for cloning and sequencing of canine NUCB2/nesfatin-1 were as follows: NUCB2/nesfatin-1 Forward, 5′- atgaggtggaggatcatctt-3′; Reverse, 5′- aagagcatggtggtctatgc-3′. </plain></SENT>
<SENT sid="39955" pm="."><plain>Total RNA extracted from a stomach sample was reverse-transcribed into cDNA using TaKaRa RNA PCR Kit (AMV) Ver.3.0 (TaKaRa, Otsu, Japan) at the following conditions, 42°C for 30 min and 99°C for 5 min. </plain></SENT>
<SENT sid="39956" pm="."><plain>PCR amplification was performed using 50 µl reactions containing 5 µl of 10X PCR buffer, 4 µl of dNTPs, 2 µl of magnesium chloride, 1 µl of each primer, 0.25 µl of LA Taq DNA polymerase (TaKaRa), 2 µl of template cDNA and 34.75 µl of distilled water. </plain></SENT>
<SENT sid="39957" pm="."><plain>The PCR protocol consisted of an initial denaturing cycle at 96°C for 2 min followed by a 35 cycle amplification step (96°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec) with a final extension cycle at 72°C for 2 min. </plain></SENT>
<SENT sid="39958" pm="."><plain>The PCR products were electrophoresed in 2% agarose gel to confirm the expected size and subcloned into pT-7 blue vectors (Novagen, Madison, WI, U.S.A.) using the Ligation Mix (DNA Ligation Kit; TaKaRa). </plain></SENT>
<SENT sid="39959" pm="."><plain>The ligated plasmid was transformed into NovaBlue E. coli cells (Novagen) and sequenced using an automated ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, U.S.A.). </plain></SENT>
</text></p><p><text><SENT sid="39960" pm="."><plain>Quantitative real-time PCR analysis of canine NUCB2/nesfatin-1 mRNA: For the quantitative analyses, total RNA samples of the 14 tissues and 4 upper gastrointestinal tracts were reverse-transcribed into cDNA using a QuantiTect Rev. </plain></SENT>
<SENT sid="39961" pm="."><plain>Transcription Kit (QIAGEN). </plain></SENT>
<SENT sid="39962" pm="."><plain>We demonstrated quantitative real-time PCR (qRT-PCR) to compare mRNA expression levels among the canine tissues. </plain></SENT>
<SENT sid="39963" pm="."><plain>The primer sequences were as follows, NUCB2/nesfatin-1 Forward, 5′- caagtgattgatgtgctggaa-3′; Reverse, 5′- gccacttgttgtcttttcagttc-3′; beta-actin Forward, 5′-gccaaccgtgagaagatgact-3′; and Reverse, 5′- cccagagtccatgacaataccag-3′. </plain></SENT>
<SENT sid="39964" pm="."><plain>The qRT-PCR reactions were carried out in triplicate with a commercial kit (Perfect Real Time SYBR Premix Ex Taq II) using an Applied Biosystems 7300 Real Time PCR Sequence Detection System (Applied Biosystems). </plain></SENT>
<SENT sid="39965" pm="."><plain>The protocol was as follows, 94°C for 10 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 34 sec. </plain></SENT>
<SENT sid="39966" pm="."><plain>Following amplification, a melting curve analysis program was performed to verify the authenticity of the amplified products by their specific melting temperatures (Applied Biosystems). </plain></SENT>
<SENT sid="39967" pm="."><plain>The resulting products were subjected to nucleotide sequencing to confirm their specificity. </plain></SENT>
<SENT sid="39968" pm="."><plain>PCR amplification was carried out in 20 µl solutions containing 1 µl of template cDNA, 0.8 µl of each specific primer (10 µM), 10 µl of SYBR Premix Ex Taq, 0.4 µl of ROX reference dye II and 7.0 µl of distilled water. </plain></SENT>
<SENT sid="39969" pm="."><plain>After qRT-PCR amplification, absolute quantification was performed according to the method of Whelan et al. [32], by establishing a linear amplification curve from 10-fold serial dilutions of cloned and sequenced plasmid DNA containing target PCR products. </plain></SENT>
<SENT sid="39970" pm="."><plain>The expression level of the beta-actin gene as a housekeeping gene was quantified by the same method, and the expression levels of the target genes were rectified by the expression levels of the beta-actin gene. </plain></SENT>
</text></p><p><text><SENT sid="39971" pm="."><plain>Feeding and sampling protocol: Four adult beagle dogs (1 castrated male and 3 spayed females, 6.5–11.8 kg body weights and 4–7 years old) were maintained in the laboratory for research purposes and served as healthy controls. </plain></SENT>
<SENT sid="39972" pm="."><plain>All dogs were fed on a commercial diet (Select Skin Care as maintenance diet, Royal Canin Japon, Tokyo, Japan) twice a day (8 am and 8 pm), and the energy intake was set at 1/2 × 1.6 × RER (BW0.75 × 70) for each feeding period (RER, resting energy requirement; BW, body weight) for the dogs [4]. </plain></SENT>
<SENT sid="39973" pm="."><plain>In order to investigate short-term effects of different nutrient composition on nesfatin-1 gene expressions of upper gastrointestinal tracts, the 4 healthy dogs were fed on the same diet for 7 days followed by diet rotations (Fig. 1Fig. 1.Feeding rotations of the dogs. </plain></SENT>
<SENT sid="39974" pm="."><plain>The dogs underwent diet regimen rotations, with each regimen for 7 days. </plain></SENT>
<SENT sid="39975" pm="."><plain>The orders of the diets are shown in Supplementary Table 1. </plain></SENT>
<SENT sid="39976" pm="."><plain>Blood was always collected on the seventh day of each diet regimen. </plain></SENT>
<SENT sid="39977" pm="."><plain>Upper gastrointestinal tract samples were collected on the last day of each diet regimen by endoscopy from the anesthetized dogs. and See Appendix: Supplementary Table 1). </plain></SENT>
<SENT sid="39978" pm="."><plain>The prescription diets used for the rotations were as follows, Select Skin Care dry diet as Control diet, Weight Control dry diet as High fiber/High protein diet, Renal dry diet as High fat/Low protein diet and Gastro Intestinal Low Fat dry diet as Low fat/High carbohydrate diet (Royal Canin Japon, See Appendix: Supplementary Table 2). </plain></SENT>
</text></p><p><text><SENT sid="39979" pm="."><plain>Three dogs (dogs 1, 3 and 4, See Appendix: Supplementary Table 2) were used for the circulating nesfatin-1 assay. </plain></SENT>
<SENT sid="39980" pm="."><plain>On the seventh day of feeding, blood samples were collected from the dogs prior and 30, 60, 120 and 180 min postprandial of the diets. </plain></SENT>
<SENT sid="39981" pm="."><plain>They were collected into chilled tubes containing EDTA-2Na and 500 KIU aprotinin (Merck Millipore, Darmstadt, Germany), and centrifuged at 1,000 g for 10 min at 4°C to obtain plasma. </plain></SENT>
<SENT sid="39982" pm="."><plain>Plasma samples were used to determine nesfatin-1 concentration, which was measured using a commercial Human Nesfatin-1 EIA Competition ELISA Kit (LifeSpan BioSciences, Inc., Seattle, WA, U.S.A.) according to the manufacturer’s protocol (the inter-assay CV and intra-assay CV were &lt;12% and &lt;10%, respectively). </plain></SENT>
</text></p><p><text><SENT sid="39983" pm="."><plain>Four dogs (dogs 1, 2, 3 and 4, See Appendix: Supplementary Table 2) were used for the NUCB2/nesfatin-1 mRNA expression assay. </plain></SENT>
<SENT sid="39984" pm="."><plain>On the last day of each interval period, the dogs underwent overnight fasting. </plain></SENT>
<SENT sid="39985" pm="."><plain>The dogs were sedated by intravenous administration of 0.25 mg/kg droperidol (Droleptan; Daiichi Sankyo Co., Ltd., Tokyo, Japan) and anesthetized by intravenous administration of 7 mg/kg propofol (Rapinovet; Intervet/Schering-Plough Animal Health Corp., Ltd., Tokyo, Japan). </plain></SENT>
<SENT sid="39986" pm="."><plain>Anesthesia was maintained by inhalation of isoflurance (Escain; Merck Ltd., Tokyo, Japan) and oxygen. </plain></SENT>
<SENT sid="39987" pm="."><plain>Stomach and small intestine samples were collected every week midmorning using an endoscope from each anesthetized animal under minimal stress conditions according to guidelines of the Nippon Veterinary and Life Science University. </plain></SENT>
<SENT sid="39988" pm="."><plain>The tissue samples were immediately transferred into RNAlater solution (Sigma) and stores at −80°C until measurement of NUCB2/nesfatin-1 mRNA expression by qRT-PCR. </plain></SENT>
<SENT sid="39989" pm="."><plain>Approval for the work was given by the Nippon Veterinary and Life Science University Animal Research Committee. </plain></SENT>
</text></p><p><text><SENT sid="39990" pm="."><plain>Statistical analyses: Data are presented as the mean ± SEM. </plain></SENT>
<SENT sid="39991" pm="."><plain>Statistical analyses were demonstrated using two-way repeated measures ANOVA for comparison of plasma nesfatin-1 and one-way repeated measures ANOVA and Bonferroni’s multiple comparison test for comparison of nesfatin-1 mRNA expressions, using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, U.S.A.). </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s2"><title><text><SENT sid="39992" pm="."><plain>RESULTS </plain></SENT>
</text></title><p><text><SENT sid="39993" pm="."><plain>cDNA cloning of canine NUCB2/nesfatin-1: Open reading frame of the canine nesfatin-1 consisted of 243 nucleotides, which encodes 81 amino acid protein sequence (registered as accession AB622125). </plain></SENT>
<SENT sid="39994" pm="."><plain>The deduced canine NUCB2/nesfatin-1 protein sequence displayed a high identity to bovine (97%), human (92%), murine (86%) and rat (84%) NUCB2/nesfatin-1 sequences. </plain></SENT>
<SENT sid="39995" pm="."><plain>Additionally, bovine, human and rodent nesfatin-1 proteins consist of 82 amino acids, although canine nesfatin-1 consists of 81 amino acids. </plain></SENT>
<SENT sid="39996" pm="."><plain>Alignment analysis revealed that the 12th amino acid had been lost from the N-terminus in the dog (See Appendix: Supplementary Fig. 1). </plain></SENT>
</text></p><p><text><SENT sid="39997" pm="."><plain>Tissue distribution of NUCB2/nesfatin-1 mRNA: NUCB2/nesfatin-1 was expressed in 10 of 14 tissues tested in the dog, and the order of the highest to the lowest was as follows, pancreas&gt;bladder&gt;stomach&gt;cerebellum&gt;esophagus&gt;small intestine&gt;spleen&gt;testis&gt;kidney&gt;cerebrum (Fig. 2aFig. 2.Values are expressed as copies per 1 ng of cDNA. </plain></SENT>
<SENT sid="39998" pm="."><plain>(a) NUCB2/nesfatin-1 mRNA expression levels in various canine tissues as determined by qRT-PCR. </plain></SENT>
<SENT sid="39999" pm="."><plain>(b) NUCB2/nesfatin-1 mRNA expression levels in endoscopically-obtained stomach (gastric corpus, gastric fundus and pyloric antrum) and duodenum samples as determined by qRT-PCR.). </plain></SENT>
<SENT sid="40000" pm="."><plain>The NUCB2/nesfatin-1 mRNA expressions of cerebellum, stomach, pancreas and bladder were higher (&gt;400 copies/ng cDNA), and those of cerebrum, esophagus, small intestine, spleen, kidney and testis were middle (100–400 copies/ng cDNA). </plain></SENT>
<SENT sid="40001" pm="."><plain>On the other hand, liver, heart, skeletal muscle and adipose tissue had poor NUCB2/nesfatin-1 mRNA expressions (&lt;100 copies/ng cDNA). </plain></SENT>
<SENT sid="40002" pm="."><plain>In NUCB2/nesfatin-1 expression of upper gastrointestinal tracts, the order of the highest to the lowest was as follows, pyloric antrum&gt;gastric fundus&gt;gastric corpus&gt;duodenum (Fig. 2b). </plain></SENT>
<SENT sid="40003" pm="."><plain>Most rich NUCB2/nesfatin-1 mRNA expression in pyloric antrum was 567 copies/ng cDNA. </plain></SENT>
</text></p><p><text><SENT sid="40004" pm="."><plain>Influence of the different dietary components on canine plasma nesfatin-1: The results of the plasma nesfatin-1 assay of the 3 healthy dogs fed on different types of diets are shown in Fig. 3Fig. 3.Mean temporal changes in postprandial plasma nesfatin-1 concentrations under different types of diets in healthy dogs. </plain></SENT>
<SENT sid="40005" pm="."><plain>Values are expressed as means ± SEM (n=3).. </plain></SENT>
<SENT sid="40006" pm="."><plain>Basal plasma nesfatin-1 concentrations did not change after 1-week feeding of different types of diets statistically, however, those after High fiber/High protein and High fat/Low protein diets tended to be higher than others. </plain></SENT>
<SENT sid="40007" pm="."><plain>Plasma nesfatin-1 concentrations did not show significant changes from prior to 180 min after the dogs were fed. </plain></SENT>
</text></p><p><text><SENT sid="40008" pm="."><plain>Influence of the different dietary components on canine NUCB2/nesfatin-1: The results of the NUCB2/nesfatin-1 mRNA expressions of upper gastrointestinal tracts (gastric corpus, pyloric antrum and duodenum) examined in the 4 healthy dogs fed on different types of diets are shown in Fig. 4Fig. 4.NUCB2/nesfatin-1 mRNA expressions in upper gastrointestinal tracts of the dogs fed on different types of diets are indicated. </plain></SENT>
<SENT sid="40009" pm="."><plain>The values were normalized by the expression levels of beta-actin gene. </plain></SENT>
<SENT sid="40010" pm="."><plain>Each value of mRNA expression was denoted as the relative value to the control diet and expressed as mean ± SEM (n=4). </plain></SENT>
<SENT sid="40011" pm="."><plain>Different alphabetic letters indicate statistically different, a vs. b, P&lt;0.001; a vs. b’, P&lt;0.05, Bonferroni’s Multiple Comparison Test.. </plain></SENT>
<SENT sid="40012" pm="."><plain>In gastric corpus, nesfatin-1 mRNA expression was 1.46-fold higher in the dogs fed on a High fiber/High protein diet, 1.10-fold higher in the dogs fed on a High fat/Low protein diet and 0.83-fold higher in the dogs fed on a Low fat/High carbohydrate diet diets comparing to those on a control diet, but the differences were not statistically significant. </plain></SENT>
<SENT sid="40013" pm="."><plain>In pyloric antrum, the nesfatin-1 mRNA expression was 1.84-fold higher in the dogs fed on a High fiber/High protein diet (P&lt;0.001), 1.48-fold higher in the dogs fed on a High fat/Low protein diet (P&lt;0.05) and 1.02-fold higher in the dogs fed on a Low fat/High carbohydrate diet (not significant) comparing to those on a control diet. </plain></SENT>
<SENT sid="40014" pm="."><plain>Moreover, the difference in High fiber/High protein diet and High fat/Low protein diet was statistically significant comparing to those on a Low fat/High carbohydrate diet, too (P&lt;0.001 and P&lt;0.05, respectively). </plain></SENT>
<SENT sid="40015" pm="."><plain>In duodenum, nesfatin-1 mRNA expression was 1.09-fold higher in the dogs fed on a High fiber/High protein diet, 1.17-fold higher in the dogs fed on a High fat/Low protein diet and 0.83-fold higher in the dogs fed on a Low fat/High carbohydrate diet comparing to those on a control diet, but the differences were not statistically significant. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s3"><title><text><SENT sid="40016" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="40017" pm="."><plain>The cloned cDNA of canine NUCB2/nesfatin-1 was highly homologous to those of other species [19]. </plain></SENT>
<SENT sid="40018" pm="."><plain>In the current study, we revealed that canine NUCB2/nesfatin-1 mRNA is abundant in pancreas, gastrointestinal tracts, testis and cerebellum. </plain></SENT>
<SENT sid="40019" pm="."><plain>In a previous paper, it has been reported that NUCB2/nesfatin-1 was much expressed in the cerebellum, stomach (especially pyloric antrum) and pancreas in rodents [35]. </plain></SENT>
<SENT sid="40020" pm="."><plain>Moreover, García et al. [9] have reported the expression of NUCB2/nesfatin-1 in Leydig cells of testis, which is under the control of developmental, nutritional and gonadotropic cues. </plain></SENT>
<SENT sid="40021" pm="."><plain>The current results are basically identical to these reports in other species. </plain></SENT>
<SENT sid="40022" pm="."><plain>However, these studies aimed at NUCB2/nesfatin-1 in limited types of tissues, and analyses in whole body have not ever been performed. </plain></SENT>
<SENT sid="40023" pm="."><plain>Therefore, there are no data about other organs that we compared. </plain></SENT>
<SENT sid="40024" pm="."><plain>In particular, we detected the highest expressions of NUCB2/nesfatin-1 in bladder, spleen and kidney, although their physiological implications are not clear. </plain></SENT>
</text></p><p><text><SENT sid="40025" pm="."><plain>In the present study, we measured plasma nesfatin-1 concentrations and quantified the NUCB2/nesfatin-1 mRNA expressions in the gastrointestinal tracts when the dogs were fed on different types of nutrient for 7 days. </plain></SENT>
<SENT sid="40026" pm="."><plain>Plasma concentrations of nesfatin-1 in the dogs were approximately 4 ng/ml, and they did not change after feeding, harmonizing the results by Watanabe et al. [31]. </plain></SENT>
<SENT sid="40027" pm="."><plain>In addition, Tsuchiya et al. [30] have reported that nesfatin-1 concentrations did not change significantly in humans by meal tests during 0–240 min. </plain></SENT>
<SENT sid="40028" pm="."><plain>These results do not harmonize the hypothesis that circulating nesfatin-1 increases postprandially and acts on brains through the blood-brain barrier to cause satiety effects. </plain></SENT>
</text></p><p><text><SENT sid="40029" pm="."><plain>On the other hand, we detected the significant change of NUCB2/nesfatin-1 mRNA expressions, i.e. High fiber/High protein diet and High fat/Low protein diet increased NUCB2/nesfatin-1 mRNA expressions in pyloric antrum significantly. </plain></SENT>
<SENT sid="40030" pm="."><plain>Those in other regions of gastrointestinal tracts (gastric corpus and duodenum) did not show significant change, but tended to be similar to that in pyloric antrum. </plain></SENT>
<SENT sid="40031" pm="."><plain>It is possible that locally produced nesfatin-1 stimulates vagal nerves to cause the satiety effects by acting on brain through the afferent nerve system. </plain></SENT>
<SENT sid="40032" pm="."><plain>However, it is no more than a hypothesis at this moment, and further studies are necessary to prove it. </plain></SENT>
<SENT sid="40033" pm="."><plain>Ramanjaneya et al. [24] have reported that the mice fed on a high fat diet for 12 or 20 weeks showed increased nesfatin-1 production in adipose tissues. </plain></SENT>
<SENT sid="40034" pm="."><plain>In the present study, we revealed that NUCB2/nesfatin-1 mRNA expressions are increased in gastrointestinal tracts after feeding of High fat (/Low protein) diet. </plain></SENT>
<SENT sid="40035" pm="."><plain>This may support the relationship between high fat diet and NUCB2/nesfation-1 production in dogs. </plain></SENT>
<SENT sid="40036" pm="."><plain>A number of studies have showed that fiber-rich foods can increase the sense of satiety and decrease short-term food intake in humans [5, 16, 22, 33], and it is also reported that fiber causes a satiety effect by gastric distension in companion animals [21]. </plain></SENT>
<SENT sid="40037" pm="."><plain>In the present study, we detected the highest NUCB2/nesfatin-1 mRNA expressions in the dogs fed on High fiber (/High protein) diet. </plain></SENT>
<SENT sid="40038" pm="."><plain>Considering the current results, it is possible that increased nesfatin-1 is another factor that may relate to satiety too. </plain></SENT>
<SENT sid="40039" pm="."><plain>Collectively, High fat/Low protein and High fiber/High protein diets increase NUCB2/nesfatin-1 production in canine stomach, and it may relate to satiety effects in dogs. </plain></SENT>
<SENT sid="40040" pm="."><plain>It is reported that contraction of the stomach at the fasted state is controlled by administrated nesfatin-1 in dogs [31], but there are no reports indicating that administered nesfatin-1 influences food consumption in dogs like rodent studies. </plain></SENT>
</text></p><p><text><SENT sid="40041" pm="."><plain>Limitations of the current study are as follows. </plain></SENT>
<SENT sid="40042" pm="."><plain>First, we used the commercial diets which were different in more than 2 kinds of dietary components. </plain></SENT>
<SENT sid="40043" pm="."><plain>Ideally, we should use diets which are different in only one nutrient, but when we change the amount of one nutrient of a food, keeping the metabolizable energy constant, we have to change the amount of other nutrients too, so it is difficult to design the desirable experimental protocol. </plain></SENT>
<SENT sid="40044" pm="."><plain>Second, there are no data which demonstrate the function of canine nesfatin-1, so the satiety effects of nesfatin-1 remain unclear in dogs. </plain></SENT>
<SENT sid="40045" pm="."><plain>It is difficult to evaluate the sense of satiety in dogs, but there are some reports describing the satiety effects in dogs objectively. </plain></SENT>
<SENT sid="40046" pm="."><plain>Jewell and Toll [13] and Bosch et al. [2] have evaluated the effects of dietary fiber on satiety in dogs, in which, voluntary food intake of an additional meal after consumption of the morning meal was found to be lower in the dogs fed on high-fiber diets. </plain></SENT>
<SENT sid="40047" pm="."><plain>Therefore, it will be a possible approach to investigate the relationship between nesfatin-1 levels and satiety effects of dietary components in dogs using the same methods for the next step. </plain></SENT>
<SENT sid="40048" pm="."><plain>Third, influences of adipose nesfatin-1 are not investigated. </plain></SENT>
<SENT sid="40049" pm="."><plain>We analyzed NUCB2/nesfatin-1 in upper gastrointestinal tracts since they are organs that contact dietary components, however, Stengel et al. [28] have reported that nesfatin-1 produced by adipose tissues influences feeding and other metabolic actions. </plain></SENT>
<SENT sid="40050" pm="."><plain>Although NUCB2/nesfatin-1 mRNA expression in canine adipose tissue was poor in the current result, further studies are necessary to prove the role of adipose nesfatin-1 in dogs. </plain></SENT>
</text></p><p><text><SENT sid="40051" pm="."><plain>In conclusion, the current study demonstrated that canine NUCB2/nasfatin-1 was very similar to those of other species in molecular structure and tissue distribution. </plain></SENT>
<SENT sid="40052" pm="."><plain>Plasma nesfatin-1 concentrations in the dogs were approximately 4 ng/ml, and they did not change after feeding. </plain></SENT>
<SENT sid="40053" pm="."><plain>On the other hand, High fiber/High protein and High fat/Low protein diets increased gastric NUCB2/nesfatin-1 at transcriptional levels. </plain></SENT>
<SENT sid="40054" pm="."><plain>These results may set the stage for further investigations of canine NUCB2/nesfatin-1, which may relate to satiety effects in dogs. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="40055" pm="."><plain>Supplementary Material </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pdf_001"><caption><title><text><SENT sid="40056" pm="."><plain>Supplementary Table </plain></SENT>
</text></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="jvms-78-411-s001.pdf" orientation="portrait" xlink:type="simple" id="d36e624" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="pdf_002"><caption><title><text><SENT sid="40057" pm="."><plain>Supplementary figure </plain></SENT>
</text></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="jvms-78-411-s002.pdf" orientation="portrait" xlink:type="simple" id="d36e629" position="anchor"/></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="40058" pm="."><plain>This research was supported in part by Scholarship Program 2010 from Japanese Society of Veterinary Clinical Nutrition. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="r1"><text><SENT sid="40059" pm="."><plain>1BonnetM. </plain></SENT>
<SENT sid="40060" pm="."><plain>S.OuelaaW.TillementV.TrouslardJ.JeanA.GonzalezB. </plain></SENT>
<SENT sid="40061" pm="."><plain>J.GourcerolG.DallaportaM.TroadecJ. </plain></SENT>
<SENT sid="40062" pm="."><plain>D.MounienL.2013. Gastric distension activates NUCB2/nesfatin-1-expressing neurons in the nucleus of the solitary tract. Regul. </plain></SENT>
<SENT sid="40063" pm="."><plain>Pept.187: 17–23. doi: 10.1016/j.regpep.2013.10.001<?supplied-pmid 24120633?>24120633 </plain></SENT>
</text></ref><ref id="r2"><text><SENT sid="40064" pm="."><plain>2BoschG.VerbruggheA.HestaM.HolstJ. </plain></SENT>
<SENT sid="40065" pm="."><plain>J.van der PoelA. </plain></SENT>
<SENT sid="40066" pm="."><plain>F.JanssensG. </plain></SENT>
<SENT sid="40067" pm="."><plain>P.HendriksW. </plain></SENT>
<SENT sid="40068" pm="."><plain>H.2009. The effects of dietary fibre type on satiety-related hormones and voluntary food intake in dogs. Br. </plain></SENT>
<SENT sid="40069" pm="."><plain>J. </plain></SENT>
<SENT sid="40070" pm="."><plain>Nutr.102: 318–325. doi: 10.1017/S0007114508149194<?supplied-pmid 19144213?>19144213 </plain></SENT>
</text></ref><ref id="r3"><text><SENT sid="40071" pm="."><plain>3BurkholderW. </plain></SENT>
<SENT sid="40072" pm="."><plain>J.TollP. </plain></SENT>
<SENT sid="40073" pm="."><plain>W.2000 Obesity. pp. </plain></SENT>
<SENT sid="40074" pm="."><plain>401–403. In: Small Animal Clinical Nutrition, 4th ed. </plain></SENT>
<SENT sid="40075" pm="."><plain>(Michael, S. H., Craig, D. T., Rebecca, L. R., Philip, R. and Lon, D. L. eds.), Mark Morris Institute, Topeka. </plain></SENT>
</text></ref><ref id="r4"><text><SENT sid="40080" pm="."><plain>4DebraekeleerJ.GrossK. </plain></SENT>
<SENT sid="40081" pm="."><plain>L.ZickerS. </plain></SENT>
<SENT sid="40082" pm="."><plain>C.2000 Normal dogs. pp. </plain></SENT>
<SENT sid="40083" pm="."><plain>213–260. In: Small Animal Clinical Nutrition, 4th ed. </plain></SENT>
<SENT sid="40084" pm="."><plain>(Michael, S. H., Craig, D. T., Rebecca, L. R., Philip, R. and Lon, D. L. eds.), Mark Morris Institute, Topeka. </plain></SENT>
</text></ref><ref id="r5"><text><SENT sid="40089" pm="."><plain>5DelargyH. </plain></SENT>
<SENT sid="40090" pm="."><plain>J.BurleyV. </plain></SENT>
<SENT sid="40091" pm="."><plain>J.O’SullivanK. </plain></SENT>
<SENT sid="40092" pm="."><plain>R.FletcherR. </plain></SENT>
<SENT sid="40093" pm="."><plain>J.BlundellJ. </plain></SENT>
<SENT sid="40094" pm="."><plain>E.1995. Effects of different soluble: insoluble fibre ratios at breakfast on 24-h pattern of dietary intake and satiety. Eur. </plain></SENT>
<SENT sid="40095" pm="."><plain>J. </plain></SENT>
<SENT sid="40096" pm="."><plain>Clin. </plain></SENT>
<SENT sid="40097" pm="."><plain>Nutr.49: 754–766. <?supplied-pmid 8536654?>8536654 </plain></SENT>
</text></ref><ref id="r6"><text><SENT sid="40098" pm="."><plain>6EdneyA. </plain></SENT>
<SENT sid="40099" pm="."><plain>T.SmithP. </plain></SENT>
<SENT sid="40100" pm="."><plain>M.1986. Study of obesity in dogs visiting veterinary practices in the United Kingdom. Vet. </plain></SENT>
<SENT sid="40101" pm="."><plain>Rec.118: 391–396. doi: 10.1136/vr.118.14.391<?supplied-pmid 3716092?>3716092 </plain></SENT>
</text></ref><ref id="r7"><text><SENT sid="40102" pm="."><plain>7FooK. </plain></SENT>
<SENT sid="40103" pm="."><plain>S.BrismarH.BrobergerC.2008. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience156: 563–579. doi: 10.1016/j.neuroscience.2008.07.054<?supplied-pmid 18761059?>18761059 </plain></SENT>
</text></ref><ref id="r8"><text><SENT sid="40104" pm="."><plain>8FooK. </plain></SENT>
<SENT sid="40105" pm="."><plain>S.BraunerH.OstensonC. </plain></SENT>
<SENT sid="40106" pm="."><plain>G.BrobergerC.2010. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J. Endocrinol.204: 255–263. doi: 10.1677/JOE-09-0254<?supplied-pmid 20032201?>20032201 </plain></SENT>
</text></ref><ref id="r9"><text><SENT sid="40108" pm="."><plain>9García-GalianoD.PinedaR.IlhanT.CastellanoJ. </plain></SENT>
<SENT sid="40109" pm="."><plain>M.Ruiz-PinoF.Sánchez-GarridoM. </plain></SENT>
<SENT sid="40110" pm="."><plain>A.VazquezM. </plain></SENT>
<SENT sid="40111" pm="."><plain>J.Sangiao-AlvarellosS.Romero-RuizA.PinillaL.DiéguezC.GaytánF.Tena-SempereM.2012. Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. Endocrinology153: 1959–1971. doi: 10.1210/en.2011-2032<?supplied-pmid 22334726?>22334726 </plain></SENT>
</text></ref><ref id="r10"><text><SENT sid="40112" pm="."><plain>10GonkowskiS.RychlikA.NowickiM.NieradkaR.BulcM.CałkaJ.2012. A population of nesfatin 1-like immunoreactive (LI) cells in the mucosal layer of the canine digestive tract. Res. </plain></SENT>
<SENT sid="40113" pm="."><plain>Vet. </plain></SENT>
<SENT sid="40114" pm="."><plain>Sci.93: 1119–1121. doi: 10.1016/j.rvsc.2012.06.002<?supplied-pmid 22749244?>22749244 </plain></SENT>
</text></ref><ref id="r11"><text><SENT sid="40115" pm="."><plain>11GonzalezR.KerbelB.ChunA.UnniappanS.2010. Molecular, cellular and physiological evidences for the anorexigenic actions of nesfatin-1 in goldfish. PLoS ONE5: e15201. doi: 10.1371/journal.pone.0015201<?supplied-pmid 21151928?>21151928 </plain></SENT>
</text></ref><ref id="r12"><text><SENT sid="40116" pm="."><plain>12IshiokaK.SolimanM. </plain></SENT>
<SENT sid="40117" pm="."><plain>M.SagawaM.NakadomoF.ShibataH.HonjohT.HashimotoA.KitamuraH.KimuraK.SaitoM.2002. Experimental and clinical studies on plasma leptin in obese dogs. J. Vet. </plain></SENT>
<SENT sid="40119" pm="."><plain>Med. </plain></SENT>
<SENT sid="40120" pm="."><plain>Sci.64: 349–353. doi: 10.1292/jvms.64.349<?supplied-pmid 12014581?>12014581 </plain></SENT>
</text></ref><ref id="r13"><text><SENT sid="40121" pm="."><plain>13JewellD. </plain></SENT>
<SENT sid="40122" pm="."><plain>E.TollP. </plain></SENT>
<SENT sid="40123" pm="."><plain>W.1996 Effects of fiber on food intake in dogs. Vet. </plain></SENT>
<SENT sid="40124" pm="."><plain>Clin. </plain></SENT>
<SENT sid="40125" pm="."><plain>Nutr.3: 115–118. </plain></SENT>
</text></ref><ref id="r14"><text><SENT sid="40126" pm="."><plain>14KealyR. </plain></SENT>
<SENT sid="40127" pm="."><plain>D.LawlerD. </plain></SENT>
<SENT sid="40128" pm="."><plain>F.BallamJ. </plain></SENT>
<SENT sid="40129" pm="."><plain>M.MantzS. </plain></SENT>
<SENT sid="40130" pm="."><plain>L.BieryD. </plain></SENT>
<SENT sid="40131" pm="."><plain>N.GreeleyE. </plain></SENT>
<SENT sid="40132" pm="."><plain>H.LustG.SegreM.SmithG. </plain></SENT>
<SENT sid="40133" pm="."><plain>K.StoweH. </plain></SENT>
<SENT sid="40134" pm="."><plain>D.2002. Effects of diet restriction on life span and age-related changes in dogs. J. Am. </plain></SENT>
<SENT sid="40136" pm="."><plain>Vet. </plain></SENT>
<SENT sid="40137" pm="."><plain>Med. </plain></SENT>
<SENT sid="40138" pm="."><plain>Assoc.220: 1315–1320. doi: 10.2460/javma.2002.220.1315<?supplied-pmid 11991408?>11991408 </plain></SENT>
</text></ref><ref id="r15"><text><SENT sid="40139" pm="."><plain>15KohnoD.NakataM.MaejimaY.ShimizuH.SedbazarU.YoshidaN.DezakiK.OnakaT.MoriM.YadaT.2008. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology149: 1295–1301. doi: 10.1210/en.2007-1276<?supplied-pmid 18048495?>18048495 </plain></SENT>
</text></ref><ref id="r16"><text><SENT sid="40140" pm="."><plain>16KrotkiewskiM.1984. Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects. Br. </plain></SENT>
<SENT sid="40141" pm="."><plain>J. </plain></SENT>
<SENT sid="40142" pm="."><plain>Nutr.52: 97–105. doi: 10.1079/BJN19840075<?supplied-pmid 6331498?>6331498 </plain></SENT>
</text></ref><ref id="r17"><text><SENT sid="40143" pm="."><plain>17MaejimaY.SedbazarU.IwasakiY.TakanoE.YadaT.2011. The nesfatin-1 anorectic neural pathway and its role in stress, circulation, and reproduction. Nippon Yakurigaku Zasshi137: 162–165. doi: 10.1254/fpj.137.162<?supplied-pmid 21478634?>21478634 </plain></SENT>
</text></ref><ref id="r18"><text><SENT sid="40144" pm="."><plain>18MaejimaY.SedbazarU.SuyamaS.KohnoD.OnakaT.TakanoE.YoshidaN.KoikeM.UchiyamaY.FujiwaraK.YashiroT.HorvathT. </plain></SENT>
<SENT sid="40145" pm="."><plain>L.DietrichM. </plain></SENT>
<SENT sid="40146" pm="."><plain>O.TanakaS.DezakiK.HashimotoK.ShimizuH.NakataM.MoriM.YadaT.2009. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab.10: 355–365. doi: 10.1016/j.cmet.2009.09.002<?supplied-pmid 19883614?>19883614 </plain></SENT>
</text></ref><ref id="r19"><text><SENT sid="40147" pm="."><plain>19Oh-IS.ShimizuH.SatohT.OkadaS.AdachiS.InoueK.EguchiH.YamamotoM.ImakiT.HashimotoK.TsuchiyaT.MondenT.HoriguchiK.YamadaM.MoriM.2006. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature443: 709–712. doi: 10.1038/nature05162<?supplied-pmid 17036007?>17036007 </plain></SENT>
</text></ref><ref id="r20"><text><SENT sid="40148" pm="."><plain>20PanW.HsuchouH.KastinA. </plain></SENT>
<SENT sid="40149" pm="."><plain>J.2007. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides28: 2223–2228. doi: 10.1016/j.peptides.2007.09.005<?supplied-pmid 17950952?>17950952 </plain></SENT>
</text></ref><ref id="r21"><text><SENT sid="40150" pm="."><plain>21PappasT. </plain></SENT>
<SENT sid="40151" pm="."><plain>N.MelendezR. </plain></SENT>
<SENT sid="40152" pm="."><plain>L.DebasH. </plain></SENT>
<SENT sid="40153" pm="."><plain>T.1989. Gastric distension is a physiologic satiety signal in the dog. Dig. </plain></SENT>
<SENT sid="40154" pm="."><plain>Dis. </plain></SENT>
<SENT sid="40155" pm="."><plain>Sci.34: 1489–1493. doi: 10.1007/BF01537098<?supplied-pmid 2791798?>2791798 </plain></SENT>
</text></ref><ref id="r22"><text><SENT sid="40156" pm="."><plain>22PasmanW. </plain></SENT>
<SENT sid="40157" pm="."><plain>J.SarisW. </plain></SENT>
<SENT sid="40158" pm="."><plain>H.WautersM. </plain></SENT>
<SENT sid="40159" pm="."><plain>A.Westerterp-PlantengaM. </plain></SENT>
<SENT sid="40160" pm="."><plain>S.1997. Effect of one week of fibre supplementation on hunger and satiety ratings and energy intake. Appetite29: 77–87. doi: 10.1006/appe.1997.0091<?supplied-pmid 9268427?>9268427 </plain></SENT>
</text></ref><ref id="r23"><text><SENT sid="40161" pm="."><plain>23PriceT. </plain></SENT>
<SENT sid="40162" pm="."><plain>O.SamsonW. </plain></SENT>
<SENT sid="40163" pm="."><plain>K.NiehoffM. </plain></SENT>
<SENT sid="40164" pm="."><plain>L.BanksW. </plain></SENT>
<SENT sid="40165" pm="."><plain>A.2007. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides28: 2372–2381. doi: 10.1016/j.peptides.2007.10.008<?supplied-pmid 18006117?>18006117 </plain></SENT>
</text></ref><ref id="r24"><text><SENT sid="40166" pm="."><plain>24RamanjaneyaM.ChenJ.BrownJ. </plain></SENT>
<SENT sid="40167" pm="."><plain>E.TripathiG.HallschmidM.PatelS.KernW.HillhouseE. </plain></SENT>
<SENT sid="40168" pm="."><plain>W.LehnertH.TanB. </plain></SENT>
<SENT sid="40169" pm="."><plain>K.RandevaH. </plain></SENT>
<SENT sid="40170" pm="."><plain>S.2010. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology151: 3169–3180. doi: 10.1210/en.2009-1358<?supplied-pmid 20427481?>20427481 </plain></SENT>
</text></ref><ref id="r25"><text><SENT sid="40171" pm="."><plain>25ShimizuH.OhsakiA.Oh-IS.OkadaS.MoriM.2009. A new anorexigenic protein, nesfatin-1. Peptides30: 995–998. doi: 10.1016/j.peptides.2009.01.002<?supplied-pmid 19452636?>19452636 </plain></SENT>
</text></ref><ref id="r26"><text><SENT sid="40172" pm="."><plain>26ShimizuH.Oh-IS.HashimotoK.NakataM.YamamotoS.YoshidaN.EguchiH.KatoI.InoueK.SatohT.OkadaS.YamadaM.YadaT.MoriM.2009. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology150: 662–671. doi: 10.1210/en.2008-0598<?supplied-pmid 19176321?>19176321 </plain></SENT>
</text></ref><ref id="r27"><text><SENT sid="40173" pm="."><plain>27StengelA.GoebelM.YakubovI.WangL.WitcherD.CoskunT.TacheY.SachsG.LambrechtN. </plain></SENT>
<SENT sid="40174" pm="."><plain>W.2009. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology150: 232–238. doi: 10.1210/en.2008-0747<?supplied-pmid 18818289?>18818289 </plain></SENT>
</text></ref><ref id="r28"><text><SENT sid="40175" pm="."><plain>28StengelA.MoriM.TachéY.2013. The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors. Obes. </plain></SENT>
<SENT sid="40176" pm="."><plain>Rev.14: 859–870. doi: 10.1111/obr.12063<?supplied-pmid 23980879?>23980879 </plain></SENT>
</text></ref><ref id="r29"><text><SENT sid="40177" pm="."><plain>29TianZ. </plain></SENT>
<SENT sid="40178" pm="."><plain>B.DengR. </plain></SENT>
<SENT sid="40179" pm="."><plain>J.SunG. </plain></SENT>
<SENT sid="40180" pm="."><plain>R.WeiL. </plain></SENT>
<SENT sid="40181" pm="."><plain>Z.KongX. </plain></SENT>
<SENT sid="40182" pm="."><plain>J.DingX. </plain></SENT>
<SENT sid="40183" pm="."><plain>L.JingX.ZhangC. </plain></SENT>
<SENT sid="40184" pm="."><plain>P.GeY. </plain></SENT>
<SENT sid="40185" pm="."><plain>L.2014. Expression of gastrointestinal nesfatin-1 and gastric emptying in ventromedial hypothalamic nucleus- and ventrolateral hypothalamic nucleus-lesioned rats. World J. Gastroenterol.20: 6897–6905. doi: 10.3748/wjg.v20.i22.6897<?supplied-pmid 24944480?>24944480 </plain></SENT>
</text></ref><ref id="r30"><text><SENT sid="40187" pm="."><plain>30TsuchiyaT.ShimizuH.YamadaM.OsakiA.Oh-IS.AriyamaY.TakahashiH.OkadaS.HashimotoK.SatohT.KojimaM.MoriM.2010. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin. </plain></SENT>
<SENT sid="40188" pm="."><plain>Endocrinol. </plain></SENT>
<SENT sid="40189" pm="."><plain>(Oxf.)73: 484–490. <?supplied-pmid 20550530?>20550530 </plain></SENT>
</text></ref><ref id="r31"><text><SENT sid="40190" pm="."><plain>31WatanabeA.MochikiE.KimuraA.KogureN.YanaiM.OgawaA.ToyomasuY.OgataK.OhnoT.SuzukiH.KuwanoH.2015. Nesfatin-1 suppresses gastric contractions and inhibits interdigestive migrating contractions in conscious dogs. Dig. </plain></SENT>
<SENT sid="40191" pm="."><plain>Dis. </plain></SENT>
<SENT sid="40192" pm="."><plain>Sci.60: 1595–1602. doi: 10.1007/s10620-014-3505-8<?supplied-pmid 25563722?>25563722 </plain></SENT>
</text></ref><ref id="r32"><text><SENT sid="40193" pm="."><plain>32WhelanJ. </plain></SENT>
<SENT sid="40194" pm="."><plain>A.RussellN. </plain></SENT>
<SENT sid="40195" pm="."><plain>B.WhelanM. </plain></SENT>
<SENT sid="40196" pm="."><plain>A.2003. A method for the absolute quantification of cDNA using real-time PCR. J. Immunol. </plain></SENT>
<SENT sid="40198" pm="."><plain>Methods278: 261–269. doi: 10.1016/S0022-1759(03)00223-0<?supplied-pmid 12957413?>12957413 </plain></SENT>
</text></ref><ref id="r33"><text><SENT sid="40199" pm="."><plain>33WilmshurstP.CrawleyJ. </plain></SENT>
<SENT sid="40200" pm="."><plain>C.1980. The measurement of gastric transit time in obese subjects using 24Na and the effects of energy content and guar gum on gastric emptying and satiety. Br. </plain></SENT>
<SENT sid="40201" pm="."><plain>J. </plain></SENT>
<SENT sid="40202" pm="."><plain>Nutr.44: 1–6. doi: 10.1079/BJN19800003<?supplied-pmid 7426600?>7426600 </plain></SENT>
</text></ref><ref id="r34"><text><SENT sid="40203" pm="."><plain>34WynneK.StanleyS.McGowanB.BloomS. </plain></SENT>
<SENT sid="40204" pm="."><plain>R.2005. Appetite control. J. Endocrinol.184: 291–318. doi: 10.1677/joe.1.05866<?supplied-pmid 15684339?>15684339 </plain></SENT>
</text></ref><ref id="r35"><text><SENT sid="40206" pm="."><plain>35ZhangA. </plain></SENT>
<SENT sid="40207" pm="."><plain>Q.LiX. </plain></SENT>
<SENT sid="40208" pm="."><plain>L.JiangC. </plain></SENT>
<SENT sid="40209" pm="."><plain>Y.LinL.ShiR. </plain></SENT>
<SENT sid="40210" pm="."><plain>H.ChenJ. </plain></SENT>
<SENT sid="40211" pm="."><plain>D.OomuraY.2010. Expression of nesfatin-1/NUCB2 in rodent digestive system. World J. Gastroenterol.16: 1735–1741. doi: 10.3748/wjg.v16.i14.1735<?supplied-pmid 20380005?>20380005 </plain></SENT>
</text></ref><ref id="r36"><text><SENT sid="40213" pm="."><plain>36ZhangW.ZhangC.FritzeD.ChaiB.LiJ.MulhollandM. </plain></SENT>
<SENT sid="40214" pm="."><plain>W.2013. Modulation of food intake by mTOR signalling in the dorsal motor nucleus of the vagus in male rats: Focus on ghrelin and nesfatin-1. Exp. </plain></SENT>
<SENT sid="40215" pm="."><plain>Physiol.98: 1696–1704. doi: 10.1113/expphysiol.2013.074930<?supplied-pmid 23955309?>23955309 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
